The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Weber, one of the highest-profile foreign CEOs in Japan, spearheaded Takeda's $59 billion takeover of British-founded Shire ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...

Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...